Ziftomenib, Ziftomenib, Cytarabine 20 mg/ml Solution for Injection/Infusion, Fludarabine phosphate 25 mg/ml Concentrate for Solution for Injection or Infusion, Ziftomenib, Cytarabine 20 mg/ml Solution for Injection/Infusion, Solu-Cortef Powder for Solution for Injection or Infusion 100 mg
Phase 1 small_molecule active
Quick answer
Ziftomenib, Ziftomenib, Cytarabine 20 mg/ml Solution for Injection/Infusion, Fludarabine phosphate 25 mg/ml Concentrate for Solution for Injection or Infusion, Ziftomenib, Cytarabine 20 mg/ml Solution for Injection/Infusion, Solu-Cortef Powder for Solution for Injection or Infusion 100 mg for Acute Myeloid Leukemia, Mixed Phenotype Acute Leukemia, Acute Lymphocytic Leukemia is a Phase 1 program (small_molecule) at AXIM BIOTECHNOLOGIES, INC. with 1 ClinicalTrials.gov record(s).
Program details
- Company
- AXIM BIOTECHNOLOGIES, INC.
- Indication
- Acute Myeloid Leukemia, Mixed Phenotype Acute Leukemia, Acute Lymphocytic Leukemia
- Phase
- Phase 1
- Modality
- small_molecule
- Status
- active